Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.
No takes yet. Share an insight, caveat, or question.
Shepherd et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: